Core Viewpoint - The company has announced its first quarter report for 2025, detailing financial data and decisions made during the board meeting, including the establishment of a wholly-owned subsidiary and the provision of loan guarantees for a subsidiary [6][23][27]. Financial Data - The first quarter financial statements are unaudited, and the company assures the accuracy and completeness of the financial information presented [3][27]. - The company plans to apply for loans totaling up to RMB 500 million to support its operations and those of its subsidiaries [8][10]. Shareholder Information - The board meeting was attended by all eight directors, and resolutions were passed unanimously regarding the first quarter report and other significant decisions [6][7]. Subsidiary Establishment - The company intends to establish a wholly-owned subsidiary named "Liuzhou Two-Sided Needle Supply Chain Co., Ltd." with a registered capital of RMB 2 million, aimed at improving sales operations and resource integration [23][25]. Loan Guarantee - The company will provide a credit guarantee of up to RMB 50 million for its subsidiary, Guangxi Two-Sided Needle Yikang Pharmaceutical Co., Ltd., to secure necessary funding for its operations [10][12][19]. - The total amount of external guarantees provided by the company is RMB 25 million, which is 1.14% of the company's latest audited net assets [20].